Long-term risk, clinical management, and healthcare resource utilization of stable patients with coronary artery disease and post-myocardial infarction in Greece - TIGREECE study.

Autor:	Anastasiadis F; Cardiologist, Pireaus, Attica, Greece., Antoniadis D; Cardiologist, Chrysoupoli, East Macedonia and Thrace, Greece., Chountis D; Internist, Athens, Attica, Greece., Mantas I; Cardiologist, General Hospital of Chalkida, Central Greece, Greece., Lekakis I; Professor of Cardiology, Attikon University General Hospital, Attica, Greece., Elisaf M; Professor of Internal Medicine, University General Hospital of Ioannina, Epirus, Greece., Karvounis C; Professor of Cardiology, AHEPA University General Hospital of Thessaloniki, Central Macedonia, Greece., Manolis A; Cardiologist, Asklepieion General Hospital of Voula, Attica, Greece., Hahalis G; Professor of Cardiology, University General Hospital of Patras, Western Greece, Greece., Kogias I; Cardiologist, General Hospital of Karditsa, Thessaly, Greece., Tourtoglou T; Head of Clinical Operations, Astrazeneca, Greece., Gourlis D; Internist, Medical Lead, Astrazeneca, Greece., Tsounis D; Cardiologist, Nea Makri, Attica, Greece. Electronic address: tsounisd@gmail.com.
Jazyk:	angličtina
Zdroj:	Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese [Hellenic J Cardiol] 2023 Jul-Aug; Vol. 72, pp. 24-33. Date of Electronic Publication: 2023 Feb 04.
DOI:	10.1016/j.hjc.2023.01.007
Abstrakt:	Background: In light of the scarcity of evidence, TIGREECE evaluated the clinical management and long-term outcomes of patients at high risk for an atherothrombotic event who have suffered a myocardial infarction (MI), managed by cardiologists/internists in routine hospital and private office settings in Greece. Methods: TIGREECE, a multicenter, 3-year prospective cohort study, enrolled patients ≥50 years old, with a history of MI 1-3 years before enrollment and with at least one of the following risk factors: age ≥65 years, diabetes mellitus requiring medication, second prior MI, multivessel coronary artery disease, and creatinine clearance 15-60 mL/min. The primary outcome was a composite of MI, unstable angina with urgent revascularization, stroke, or all-cause death. Results: Between 5 June 2014 and 25 July 2015, 305 eligible consented patients (median age: 67.3 years; 81.3% males; 14.8% active smokers; 80.7% overweight/obese) were enrolled; 52.5% had ≥2 qualifying risk factors. The median time from the index MI [ST-segment elevation myocardial infarction (STEMI) in 51.1%, non-STEMI in 33.1%] to enrollment was 1.7 years. Of the patients, 65.9% had been discharged on dual antiplatelet therapy. At enrollment, 94.4% were receiving antiplatelets: 60.0% single [acetylsalicylic acid (ASA): 43.3%; clopidogrel: 15.7%] and 34.4% dual (ASA + clopidogrel: 31.8%) therapy. The Kaplan-Meier estimated 3-year primary composite event rate was 9.3% [95% confidence interval (CI): 6.4-13.0), and the ischemic composite event rate was 6.7% (95% CI: 4.2-9.9). Conclusions: Study results indicate that in the routine care of Greece one in ten patients experience a recurring cardiovascular event or death, mainly of ischemic origin, 1-3 years post-MI. (Copyright © 2023 Hellenic Society of Cardiology. Published by Elsevier B.V. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu